Pattern recognition receptors (PRRs) are members of innate immunity, playing pivotal role in several immunological reactions. They are known to act as a bridge between innate and adaptive immunity. They are expressed on several normal cell types but have been shown with increasing frequency on/in tumor cells. Significance of this phenomenon is largely unknown, but it has been shown by several authors that they, predominantly Toll-like receptors (TLRs), act in the interest of tumor, by promotion of its growth and spreading. Preparation of artificial of TLRs ligands (agonists) paved the way to use them as a therapeutic agents for cancer, so far in a limited scale. Agonists may be combined with conventional anti-cancer modalities with apparently promising results. PRRs recognizing nucleic acids such as RIG-1 like receptors (sensing RNA) and STING (sensing DNA) constitute a novel promising approach for cancer immunotherapy.

中文翻译：

---

模式识别受体在恶性肿瘤中的意义和作用。

模式识别受体（PRR）是先天免疫的成员，在几种免疫反应中起关键作用。众所周知，它们充当先天免疫和适应性免疫之间的桥梁。它们在几种正常细胞类型上表达，但在肿瘤细胞上/中的频率不断增加。这种现象的意义在很大程度上是未知的，但几位作者已经表明，它们主要是Toll样受体（TLR），通过促进肿瘤的生长和扩散而为肿瘤服务。迄今为止，人工制备TLRs配体（激动剂）为将其用作癌症治疗剂铺平了道路，目前规模有限。激动剂可以与常规的抗癌方式结合使用，具有明显的前景。